Myriad Genetics (NASDAQ:MYGN - Get Free Report) updated its fourth quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.03-0.04 for the period, compared to the consensus EPS estimate of $0.03. The company issued revenue guidance of $209-211 million, compared to the consensus revenue estimate of $212.87 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.
Myriad Genetics Trading Down 3.9 %
MYGN stock traded down $0.53 during mid-day trading on Wednesday, reaching $13.15. The company had a trading volume of 853,375 shares, compared to its average volume of 873,184. The company has a market capitalization of $1.20 billion, a PE ratio of -10.12 and a beta of 1.89. The firm has a 50 day moving average of $14.98 and a 200 day moving average of $22.10. Myriad Genetics has a 12 month low of $12.81 and a 12 month high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.
Analyst Ratings Changes
Several research analysts have commented on MYGN shares. Piper Sandler reduced their price objective on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, November 11th. Leerink Partnrs lowered Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. UBS Group started coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $18.00 price objective for the company. Bank of America dropped their target price on shares of Myriad Genetics from $15.00 to $13.00 and set an "underperform" rating on the stock in a report on Friday, December 13th. Finally, Morgan Stanley reduced their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating for the company in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Myriad Genetics currently has a consensus rating of "Hold" and a consensus target price of $24.27.
Read Our Latest Stock Report on MYGN
About Myriad Genetics
(
Get Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Stories
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
